A Phase 3 interventional study of adalimumab and placebo in Hidradenitis Suppurativa (HS), sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-07-07.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hidradenitis Suppurativa by AbbVie — 2 open to participants now, 5 under way, 2 of them phase 3. Hidradenitis Suppurativa · AbbVie.
Among the 18 studies in Hidradenitis Suppurativa by AbbVie, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2011, is one of 6 in phase 3, and was the 1st registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →2 of the 18 studies in Hidradenitis Suppurativa by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in Argentina, Canada, Colombia and 15 more countries
Ages 12+
AbbVie · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 307 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 243 across the 11 interventional studies, 106 across the 6 observational. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
3 of the studies in Hidradenitis Suppurativa by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06524635AbbVieA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | 2027-02 |
| NCT07136467AbbVieA Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Hidradenitis Suppurativa by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
The clinical trial identifier is PIONEER I. The purpose of this study is to evaluate the safety of adalimumab and to determine how well it works in the treatment of adults with moderate to severe HS. HS is a chronic skin disease that creates red, swollen, painful bumps which can break open to combine and form tunnels in the skin and scars. Sometimes these bumps can heal themselves quickly and sometimes they will become much worse and create sores that heal with multiple combined scars, or areas that do not heal. In this study, approximately 300 adults will be enrolled at treatment centers worldwide. Subject participation in this study will be up to 50 weeks. There will be a screening period, which will last from 7 to 30 days, and a study treatment period of up to 36 weeks. Study visits occur at Screening, Baseline, and Weeks 2, 4, 8, 12, 14, 16, 20, 24, 28, 32 and 36 (or sooner if subject leaves the study before Week 36). The study is divided into two treatment periods. The first period (Period A) will last 12 weeks and the second period (Period B) will last up to 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
If entering the study on concomitant oral analgesics for non-HS related pain:
Placebo for 12 weeks.
Biological: placebo
Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
Biological: adalimumab
Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
Biological: adalimumab · Biological: placebo
Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
Biological: adalimumab · Biological: placebo
Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
Biological: adalimumab
Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
Biological: adalimumab
Adalimumab pre-filled syringe, administered by subcutaneous injection
Also known as: Humira
Placebo pre-filled syringe, administered by subcutaneous injection
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
HiSCR was defined as at least a 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count at Week 12 relative to Baseline. Data are presented for all participants and by baseline Hurley Stage (Stage 1: Abscess formation, single or multiple, without sinus tracts and scarring; Stage II: One or more widely separated recurrent abscesses with tract formation and scars. A participant with at least 1 anatomic region with Hurley Stage II disease and with no anatomic regions with Hurley Stage III disease was classified as Hurley Stage II; and Stage III: Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement. A participant with at least 1 anatomic region with Hurley Stage III disease was classified as Hurley Stage III). Non-responder imputation (NRI): Participants with missing data were considered non-responders.
Time frame: Baseline (Week 0) up to Week 12
Percentage of Participants With Baseline Hurley Stage II Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12
The percentage of participants with AN counts lowered to 0, 1, or 2 at Week 12 among participants with Hurley Stage II at Baseline. NRI: Participants with missing data were considered non-responders.
Time frame: Baseline (Week 0) up to Week 12
Percentage of Participants Achieving At Least 30% Reduction and At Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 12 Among Participants With Baseline Skin Pain NRS ≥ 3
The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) - at worst at Week 12 among participants with Baseline NRS ≥ 3 are presented. Weekly averages of daily assessments were analyzed. NRI: Participants with missing data were considered non-responders.
Time frame: Baseline (Week 0) up to Week 12
Change From Baseline to Week 12 in Modified Sartorius Score
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; No-6 points). The total Sartorius score is the sum of the 12 regional scores. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit within the particular period for efficacy measures was carried forward to impute missing data at later visits in the same period. Baseline efficacy evaluations were not carried forward.
Time frame: Baseline (Week 0) and Week 12
Participants ≥ 18 years of age with HS for at least 1 year prior to Baseline and HS lesions present in at least 2 distinct anatomical areas (one of which must be at least Hurley Stage II or III) who had experienced inadequate response to ≥ 90 day treatment of oral antibiotics for HS were eligible for enrolment in the study.
| Milestone | Placebo | Adalimumab Every Week (EW) | Placebo/Adalimumab Every Week (EW) | Adalimumab Every Week (EW)/Placebo | Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW) | Adalimumab Every Week (EW)/Adalimumab Every Week (EW) |
|---|---|---|---|---|---|---|
| Started | 154 | 153 | 0 | 0 | 0 | 0 |
| Received study drug | 152 | 153 | 0 | 0 | 0 | 0 |
| Completed | 145 | 145 | 0 | 0 | 0 | 0 |
| Not completed | 9 | 8 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Adalimumab Every Week (EW) | Placebo/Adalimumab Every Week (EW) | Adalimumab Every Week (EW)/Placebo | Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW) | Adalimumab Every Week (EW)/Adalimumab Every Week (EW) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 145 | 49 | 48 | 48 |
| Completed | 0 | 0 | 93 | 22 | 27 | 28 |
| Not completed | 0 | 0 | 52 | 27 | 21 | 20 |
| Withdrew: Adverse event | 0 | 0 | 6 | 1 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 5 | 0 | 0 | 2 |
| Withdrew: Loss/abscence of response (per protocol) | 0 | 0 | 30 | 23 | 18 | 13 |
| Withdrew: Lost to follow-up | 0 | 0 | 5 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 5 | 1 | 1 | 2 |
HiSCR was defined as at least a 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count at Week 12 relative to Baseline. Data are presented for all participants and by baseline Hurley Stage (Stage 1: Abscess formation, single or multiple, without sinus tracts and scarring; Stage II: One or more widely separated recurrent abscesses with tract formation and scars. A participant with at least 1 anatomic region with Hurley Stage II disease and with no anatomic regions with Hurley Stage III disease was classified as Hurley Stage II; and Stage III: Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement. A participant with at least 1 anatomic region with Hurley Stage III disease was classified as Hurley Stage III). Non-responder imputation (NRI): Participants with missing data were considered non-responders.
| percentage of participants | Placebo | Adalimumab Every Week (EW) | Placebo - Baseline Hurley Stage II | Placebo - Baseline Hurley Stage III | Adalimumab Every Week (EW) - Baseline Hurley Stage II | Adalimumab Every Week (ew) - Baseline Hurley Stage III |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | 26.0 | 41.8 | 29.8 | 21.4 | 44.6 | 38.6 |
The percentage of participants with AN counts lowered to 0, 1, or 2 at Week 12 among participants with Hurley Stage II at Baseline. NRI: Participants with missing data were considered non-responders.
| percentage of participants | Placebo - Baseline Hurley Stage II | Adalimumab Every Week (EW) - Baseline Hurley Stage II |
|---|---|---|
| Percentage of Participants With Baseline Hurley Stage II Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12 | 28.6 | 28.9 |
The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) - at worst at Week 12 among participants with Baseline NRS ≥ 3 are presented. Weekly averages of daily assessments were analyzed. NRI: Participants with missing data were considered non-responders.
| percentage of participants | Placebo - Baseline NRS at Worst ≥ 3 | Adalimumab Every Week (EW) - Baseline NRS at Worst ≥ 3 |
|---|---|---|
| Percentage of Participants Achieving At Least 30% Reduction and At Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 12 Among Participants With Baseline Skin Pain NRS ≥ 3 | 24.8 | 27.9 |
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; No-6 points). The total Sartorius score is the sum of the 12 regional scores. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit within the particular period for efficacy measures was carried forward to impute missing data at later visits in the same period. Baseline efficacy evaluations were not carried forward.
| units on a scale | Placebo | Adalimumab Every Week (EW) |
|---|---|---|
| Change From Baseline to Week 12 in Modified Sartorius Score | -15.7 ± 4 | -24.4 ± 3.97 |
Collected over Adverse Events were collected from first dose of study drug until 70 days following last dose of study drug (46 weeks); Serious Adverse Events were collected from the time that informed consent was obtained (up to 50 weeks).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Period 1) | — | 5/152 (3.3%) | 81/152 (53.3%) |
| Adalimumab EW (Period 1) | — | 3/153 (2%) | 64/153 (41.8%) |
| Placebo/Adalimumab EW (Period 2) | — | 5/145 (3.4%) | 68/145 (46.9%) |
| Adalimumab EW/Placebo (Period 2) | — | 2/49 (4.1%) | 30/49 (61.2%) |
| Adalimumab EW/Adalimumab EOW (Period 2) | — | 3/48 (6.3%) | 24/48 (50%) |
| Adalimumab EW/Adalimumab EW (Period 2) | — | 1/48 (2.1%) | 28/48 (58.3%) |
| Event | Placebo (Period 1) | Adalimumab EW (Period 1) | Placebo/Adalimumab EW (Period 2) | Adalimumab EW/Placebo (Period 2) | Adalimumab EW/Adalimumab EOW (Period 2) | Adalimumab EW/Adalimumab EW (Period 2) |
|---|---|---|---|---|---|---|
| HIDRADENITISSkin and subcutaneous tissue disorders | 3/152 | 1/153 | 2/145 | 2/49 | 2/48 | 0/48 |
| ECTOPIC PREGNANCYPregnancy, puerperium and perinatal conditions | 0/152 | 0/153 | 1/145 | 0/49 | 0/48 | 1/48 |
| ABORTION INDUCEDSurgical and medical procedures | 0/152 | 0/153 | 0/145 | 0/49 | 1/48 | 0/48 |
| ABDOMINAL PAINGastrointestinal disorders | 0/152 | 0/153 | 1/145 | 0/49 | 0/48 | 0/48 |
| PNEUMONIAInfections and infestations | 0/152 | 0/153 | 1/145 | 0/49 | 0/48 | 0/48 |
| HEPATITIS A ANTIBODY POSITIVEInvestigations | 0/152 | 0/153 | 1/145 | 0/49 | 0/48 | 0/48 |
| LIVER FUNCTION TEST ABNORMALInvestigations | 0/152 | 0/153 | 1/145 | 0/49 | 0/48 | 0/48 |
| EFFUSIONGeneral disorders | 1/152 | 0/153 | 0/145 | 0/49 | 0/48 | 0/48 |
| INTERVERTEBRAL DISC CALCIFICATIONMusculoskeletal and connective tissue disorders | 1/152 | 0/153 | 0/145 | 0/49 | 0/48 | 0/48 |
| TENDONITISMusculoskeletal and connective tissue disorders | 1/152 | 0/153 | 0/145 | 0/49 | 0/48 | 0/48 |
| Event | Placebo (Period 1) | Adalimumab EW (Period 1) | Placebo/Adalimumab EW (Period 2) | Adalimumab EW/Placebo (Period 2) | Adalimumab EW/Adalimumab EOW (Period 2) | Adalimumab EW/Adalimumab EW (Period 2) |
|---|---|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 16/152 | 9/153 | 11/145 | 9/49 | 1/48 | 3/48 |
| HIDRADENITISSkin and subcutaneous tissue disorders | 17/152 | 13/153 | 14/145 | 8/49 | 7/48 | 2/48 |
| HEADACHENervous system disorders | 15/152 | 14/153 | 9/145 | 4/49 | 3/48 | 2/48 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 4/152 | 5/153 | 5/145 | 2/49 | 3/48 | 4/48 |
| PYREXIAGeneral disorders | 3/152 | 1/153 | 2/145 | 0/49 | 3/48 | 2/48 |
| DERMATITIS CONTACTSkin and subcutaneous tissue disorders | 1/152 | 0/153 | 1/145 | 0/49 | 3/48 | 0/48 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/152 | 3/153 | 1/145 | 3/49 | 1/48 | 1/48 |
| ANAEMIABlood and lymphatic system disorders | 1/152 | 1/153 | 1/145 | 1/49 | 0/48 | 2/48 |
| GASTRITISGastrointestinal disorders | 0/152 | 0/153 | 0/145 | 0/49 | 0/48 | 2/48 |
| NAUSEAGastrointestinal disorders | 4/152 | 3/153 | 6/145 | 0/49 | 0/48 | 2/48 |
| Age, Continuous(years) | Placebo | Adalimumab Every Week (EW) | Total |
|---|---|---|---|
| Mean | 37.8 ± 11.33 | 36.2 ± 10.83 | 37.0 ± 11.10 |
| Sex: Female, Male(Participants) | Placebo | Adalimumab Every Week (EW) | Total |
|---|---|---|---|
| Female | 105 | 91 | 196 |
| Male | 49 | 62 | 111 |
No study locations are listed for this record.
The record gives a start of Nov 2011, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 9 months after primary completion. A results delay was requested in Jan 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →